Tokyo, May 11, 2006 (JCN) - On May 10, Kissei Pharmaceutical and Daiichi Pharmaceutical jointly announced that they will launch URIEF Cap. 2mg/ 4mg (silodosin), an agent for treating urination disorder associated with benign prostatic hypertrophy (BPH), on May 11.
